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Abstract: Management of metastatic or advanced prostate cancer has acquired several therapeutic
approaches that have drastically changed the course of the disease. In particular due to the high
sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone
production or binding to nuclear receptor have been evaluated and adopted in clinical practice.
However, despite several hormonal treatments being available nowadays for the management of
advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the
development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this
process are of particular and increasing interest as these are potentially related to the identification
of new targetable pathways and to the development of new drugs able to improve our patients’
clinical outcomes.
Keywords: hormone inhibition resistance; prostate cancer (PCa), castration-resistance PCa; AR splice
variants; epigenetic mechanisms
1. Introduction
Prostate Cancer (PCa) is the most common malignancy in men [1]. Early stages of the disease could
be managed by different approaches, including non-invasive approaches (watchful waiting and active
surveillance) or radical approaches represented by radiation therapy, surgery or brachytherapy [2–8].
Similarly to early stages, advanced stages of the disease could benefit from several approaches.
However, androgen deprivation therapy (ADT) alone or in combination with other systemic treatments
(abiraterone or docetaxel) in high-risk newly diagnosed metastatic patients, has been the cornerstone
of advanced prostate cancer management [9–14]. Due to the high sensitivity of tumor cells to hormone
deprivation therapy, the administration of ADT results in significant clinical benefit and can prolong the
survival of patients. Nonetheless, after a variable time of ADT sensitivity (12–24 months), tumor cells
could escape from hormone inhibition and lead to disease progression. This is due to the development
of castration resistant prostate cancer (CRPC), which is defined as a prostate cancer that has progressed
despite castrate levels of serum testosterone (<50 ng/dL). The acquisition of castration resistant
Cells 2019, 8, 43; doi:10.3390/cells8010043 www.mdpi.com/journal/cells
Cells 2019, 8, 43 2 of 15
status does not mean that tumors cells are insensible to hormone inhibition. New anti-androgens
are able to improve hormone depletion or androgen receptor inhibition resulting in clinical benefit
in this population as well. The administration of these agents in early phases of the disease, such as
non-metastatic prostate cancer, has also demonstrated to improve biochemical progression of the
disease [15–22]. Unfortunately, tumor cells develop different mechanisms that are able to overcome
these hormonal pressures and become resistant to these treatments after a variable time of response.
The identification of molecular and genetic mechanisms related to the development of castration
resistant prostate cancer as well as the strategies adopted by tumors for escape from new anti-androgen
agents are of particular interest, as new therapeutic strategies are strongly needed to improve patient’s
outcomes [23].
One of the most important obstacles in this line of work is the availability of patients’ tumor
tissue. As re-biopsy can be difficult, different approaches have been tested to acquire cells and monitor
cells genomic expression modification during treatment. In vitro studies could not reflect the exact
genomic modification observed in our patients. The research of circulating tumor cells or circulating
tumor DNA represent a promising approach, even if to date only one device (CellSearch®) has been
approved [24,25].
In this review, we wanted to summarize the current knowledge about cellular and genomic
modification related to the acquisition of resistance to hormone inhibition; in addition, we wanted to
focus our attention to possible strategies to overcome these mechanisms and ongoing clinical trials.
2. Androgen Receptor and Splice Variants
All prostate cells, both normal glandular epithelium and cancer cells, are strictly dependent on
androgens, as they express the human androgen receptor (AR). The AR gene is mapped on chromosome
Xp11-12 and belongs to the steroid hormone receptor genes family. The full-length AR (AR-FL) contains
a N-terminal domain (NTD), encoded by exon 1 and that contributes in regulating the transcription of
the AR gene, a DNA-binding domain (DBD), encoded by exon 2 and 3, a hinge region, and a ligand
binding domain (LBD), encoded by exons 4–8 and which recognize the hormone with specificity and
selectivity [26,27].
The AR is a ligand-dependent transcription factor activated by androgen hormones: in the absence
of ligands (dihydrotestosterone and testosterone) it is located in the cell cytoplasm and translocates
into the nucleus once the androgen hormone binds it. In the nucleus, the AR dimerizes creating a
homodimer, binds through its DBD to androgen response elements (ARE) in the promoter regions
of androgen response genes, recruits coregulatory proteins and epigenetic factors and stimulates
downstream expression of genes that promote cell proliferation and survival [26,27].
The regulatory activity of the AR upon cellular survival makes its persistent activation a
fundamental process at the basis of prostate cancer cells’ development and progression.
AR’s gene can undergo alternative splicing that generates constitutive active ARs independent
from the presence of the ligand. AR splice variants (AR-Vs) can be characterized by the deletion of
the LBD, which acts as a repressor for the receptor, or of the NTD, disrupting important regions that
interacts with activation function 2 (AF2) in the LBD resulting in enhanced activation of AF2 and
AR-mediated gene activation [28].
Many AR splice variants have been identified in prostate cancer and have been associated with
the development of resistance to ADT, the most widely studied and clinically meaningful being the
AR-V7 (or AR3) and the ARv567es (or AR-V12). AR-FL and the main splice variants structures are
represented in Figure 1.
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Figure 1. Androgen receptor (AR) and splice variants. AR-FL: AR full length. NTD: N-terminal domain. 
DBD: DNA-binding domain. LBD: ligand binding domain. CE3: cryptic exon 3. 
ARv567es lacks the exons 5–7 that encode the LBD but retains the hinge region of exon 4 
necessary for nuclear translocation, producing a constitutively active AR isoform with transcriptional 
activity independent from the ligand. This variant can be expressed in benign and malign prostate 
tissues, however, its levels increase during ADT creating a state of resistance to castration. [26,29] 
AR-V7 is a truncated isoform of the AR derived from aberrant mRNA splicing of AR exons 1, 2, 
3, inclusion of the cryptic exon 3 (CE3) and loss of exons 4–8 that encode the LBD of the AR-FL. As a 
result, AR-V7 lacks the LBD and contains in its cryptic exon the NLS, allowing an intra-nuclear 
localization independent of the ligand and persistent activation of AR leading to an excess of survival 
signaling and growth of PCa cells. The independent activity of AR-V7 from the ligand is at the basis of 
the resistance to anti-androgen therapies and the development of castration resistant disease 
[26,27,30]. 
AR-V7 has been associated with poor prognosis in PCa metastatic to the bones [31], increased risk 
of biochemical disease recurrence after radical prostatectomy [32], and progression supporting 
epithelial-to-mesenchymal transition that contributes to metastatic spreading [33]. Furthermore, the 
main area of interest regarding AR-V7 is its involvement in developing resistance to anti-androgen 
treatments leading to a state of castration resistance, as explained later. 
3. Mechanisms of Resistance to Therapies 
AR alterations have been associated not only with the development of the state of castration 
resistance but also to resistance to abiraterone and enzalutamide. Many genetic and epigenetic 
mechanisms lie beneath this state of resistance. Resistance to AR-targeted therapies in CRPC can be 
attributed to various mechanisms corresponding to different histological, clinical, and molecular 
profiles: restored AR signaling, AR bypass signaling, and complete AR independence [34]. 
Restored AR signaling can be due to molecular alterations like AR-activating mutations, AR 
active splice variants, and intratumoral dihydrotestosterone synthesis from adrenal precursors. 
In a minority of patients with CRPC, AR activating mutations in the LBD have been found 
through genomic sequencing studies, the principal four point mutations being L702H, W742C, H875Y, 
and T878A [35]. AR carrying T878A and H875Y mutations are activated, rather than inhibited, by the 
anti-androgens nilutamide and flutamide, resulting in transcriptional induction of AR target genes 
during anti-androgen therapy [36]. Similarly, W742C mutations resulted in enhanced AR 
transcriptional activity driven by bicalutamide [34,37]. H875Y, T878A, and L720H (not linked to 
anti-androgen resistance) are more frequent that W742C, even though bicalutamide therapy is the 
most currently used in clinical practice. The explanation proposed is that AR with these mutations can 
be promiscuously activated by other steroid ligands (adrenal androgens, oestrogen, and progesterone 
(or in the case of L702H, by glucocorticoids), thus leading to disease progression [34,38,39]. 
Figure 1. Androgen receptor (AR) and splice variants. AR-FL: AR full length. NTD: N-terminal domain.
DBD: DNA-binding domain. LBD: ligand binding domain. CE3: cryptic exon 3.
ARv567es lacks the exons 5–7 that encode the LBD but retains the hinge region of exon 4 necessary
for nuclear translocation, producing a constitutively active AR isoform with transcriptional activity
independent from the ligand. This variant can be expressed in benign and malign prostate tissues,
however, its levels increase during ADT creating a state of resistance to castration [26,29].
AR-V7 is a truncated isoform of the AR derived from aberrant mRNA splicing of AR exons 1,
2, 3, inclusion of the cryptic exon 3 (CE3) and loss of exons 4–8 that encode the LBD of the AR-FL.
As a result, AR-V7 lacks the LBD and contains in its cryptic exon the NLS, allowing an intra-nuclear
localization independent of the ligand and persistent activation of AR leading to an excess of survival
signaling and growth of PCa cells. The independent activity of AR-V7 from the ligand is at the basis of
the resistance to anti-androgen therapies and the development of castration resistant disease [26,27,30].
AR-V7 has been associated with poor prognosis in PCa metastatic to the bones [31], increased risk
of biochemical disease recurrence after radical prostatectomy [32], and progression supporting
epithelial-to-mesenchymal transition that contributes to metastatic spreading [33]. Furthermore,
the main area of interest regarding AR-V7 is its involvement in developing resistance to anti-androgen
treatments leading to a state of castration resistance, as explained later.
3. Mechanisms of Resist nce to Therapies
AR alterations have been associated not only with the development of the state of castration
resistance but also to resistance to abiraterone and enzalutamide. Many genetic and epigenetic
mechanisms lie beneath this state of resistance. Resistance to AR-targeted therapies in CRPC can
be attributed to various mechanisms corresponding to different histological, clinical, and molecular
profiles: restored AR signaling, AR bypass signaling, and complete AR independence [34].
Restored AR signaling can be due to molecular alterations like AR-activating mutations, AR active
splice variants, and intratumoral dihydrotestosterone synthesis from adrenal precursors.
In a minority of patients with CRPC, AR activating mutations in the LBD have been found
through genomic sequencing studies, the principal four point mutations being L702H, W742C, H875Y,
and T878A [35]. AR carrying T878A and H875Y mutations are activated, rather than inhibited,
by the anti-androgens nilutamide and flutamide, resulting in transcriptional induction of AR target
genes during anti-androgen therapy [36]. Similarly, W742C mutations resulted in enhanced AR
transcriptional activity driven by bicalutamide [34,37]. H875Y, T878A, and L720H (not linked to
anti-androgen resistance) are more frequent that W742C, even though bicalutamide therapy is the
most currently used in clinical practice. The explanation proposed is that AR with these mutations can
be promiscuously activated by other steroid ligands (adrenal androgens, oestrogen, and progesterone
(or in the case of L702H, by glucocorticoids), thus leading to disease progression [34,38,39].
AR splice variants have been implicated in developing of acquired resistance to ADT, abiraterone,
and enzalutamide. The structural alterations of AR-Vs confer androgen-independent activity to the
AR isoforms that is correlated with nuclear localization independently by the presence of the ligand.
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AR-V567es and murine mAR-V4 maintain exons 3 and 4 that are responsible for the complete nuclear
localization signal, while the other isoforms are truncated after exon 3 and are mostly cytoplasmic.
AR-V7 is an exception, because it has constitutive nuclear localization and transcriptional activity
without a full nuclear localization signal [26]. The selective pressure of androgen deprivation therapies
seems to select AR-V7 expressing clones resistant to these therapies: as a result, AR-V7 expression
appears higher in CRPC than in hormone naïve PCa and is enhanced after enzalutamide or abiraterone
therapy [30]. Prostate cancer cells and CRPC xenografts under enzalutamide or abiraterone present a
high expression of LBD-truncated AR-V7 and AR-V567es that produce an overexpression of UBE2C
gene leading to treatment resistance [40].
In preclinical studies, knockdown of these variants conferred sensitivity to enzalutamide,
underlining their role in the development of resistance to enzalutamide by persistently activating the
AR-transcriptional program [41]. Furthermore, the finding that AR-V7 protein expression between
different metastases in the same patient is heterogeneous could indicate that the resistance to endocrine
therapies could rely on multiple mechanisms, suggesting that the therapeutic approach should be
multiple as well [30]. The increasing knowledge that AR-V7 expression could be a mechanism of
developing castration resistance is underling the importance of targeting AR-V7 with novel therapeutic
strategies when the tumor is still sensitive to ADT in order to maintain a longer state of castration
sensitivity and improve patient’s outcome.
Another mechanism of resistance to androgen receptor inhibitors can be bypassing AR signaling
by activating the downstream hormone receptor pathway through a different hormone receptor
like glucocorticoid receptor, thus overcoming AR dependency [34]. Furthermore, resistance to
anti-androgen therapies can be due to a state of complete androgen receptor independence. It is
known that tumor molecular heterogeneity can lead to a mixture of cells that express different levels
of AR. In addition, after enzalutamide or abiraterone treatment, the tumor can progress with more
aggressive variants characterized by a reduced or absent AR expression and histological features of
neuroendocrine differentiation. This latter type of PCa express molecular alterations like loss of RB1,
PTEN and TP53 mutations, amplification of MYCN and Aurora kinase A [34].
4. Epigenetic Mechanisms
Genetic and epigenetic alteration contribute to the clinical behavior of prostate cancer,
which ranges from indolent tumors to more aggressive ones. Epigenetic changes include DNA
methylation and histone acetylation and deacetylation, which can occur in various genes and may
represent a potential therapeutic target.
DNA methylation mechanisms associated with prostate cancer development, and progression
are: DNA hypermethylation of CpG sites in gene-promoter regions due to DNA-methyltransferases
that lead to transcriptional silencing and DNA methylation in the gene body [42].
Many genes have been implicated in DNA methylation changes correlated to prostate
carcinogenesis and tumor progression. Among them, hypermethylation of the AR promoter and
the consequent loss of AR expression was described in up to 30% of CRPCs [43].
Geybels et al. [44] investigated the differences in DNA methylation between malign and benign
prostate tissue and identified three genes (SCGB3A1, HIF3A, AOX1) differently methylated between
the two tissues associated with promoter methylation and reduced gene expression.
Furthermore, a study of epigenome-wide DNA methylation profiling by the same authors
found different methylated CpGs in five genes (PI15, ALKBH5, ATP11A, FHAD1, KLHL8) and
three intergenic regions that differ in metastatic lethal prostate cancers and non-recurrent ones [45].
Another study found an association of CpGs sites hypermethylation of FLNC, EFS, ECRG4, PITX2,
PDLIM4, and KCNMA1 genes and local and systemic recurrence [46].
DNA-methyltransferase (DNMTs) are a class of enzymes that work in association with the
apoptosis-modulating protein DAXX. The latter is a transcription repressor that promotes chromosome
stability: it has been found overexpressed in PCa and its expression level has been correlated with the
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Gleason score and cancer development [47]. DAXX targets DNMT1 onto specific sites in the genome
resulting in their hypermethylation and epigenetic silencing [48].
Histone modifications are another epigenetic mechanism controlling gene expression correlated
with development and progression of PCa and consist of posttranslational changes in the N-terminal
tails of histones: acetylation/deacetylation, methylation, phosphorylation, deamination, citrullination,
ubiquitination, and ADP ribosylation [49]. The enzymes that regulate the acetylation status of
histones are histone acetyltransferases (HATs) and histone deacetylases (HDACs). The acetylation of
histones mediated by HATs result in an open chromatin structure that makes DNA more accessible
by transcription factors. HATs can be distinguished into type A, located in the nucleus, and type B,
located in the cytoplasm. Some type A HATs have been associated with proliferation and disease
progression in PCa, like p300, PCAF, and Tip60 [42]. Acetylation of histone H3 near the AR-bound
chromatin has been shown to reduce androgen dependence in CRPC models [50]. On the other
hand, deacetylation of core histones in the N-terminal regions results in lower DNA accessibility
and in gene silencing. HDAC 1 and 3 are involved in modulation and transcription of AR and
the inhibition of these enzyme resulted in decreased AR synthesis [42]. HDACs can deacetylate
the AR, thus inhibiting its activity with various mechanisms like regulation of heat-shock protein
90, a chaperone that controls AR nuclear localization and activation through its acetylation or
deacetylation [51]. Furthermore, HDAC sirtuin (SIRT) 1 can regulate cellular growth through AR
deacetylation [52], while downregulation of SIRT2 deacetylase can lead to acetylation of histone H3K18,
which has been associated with poorer outcome and decreased sensitivity to ADT [43,53].
The enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase enzyme member of the
Polycomb Repressive Complex 2 (PRC2) [54]. EZH2 represses lineage specifying factors, thus favoring
metastatic progression by promoting stemness and epithelial-mesenchymal transition [43].
EZH2 controls several transcriptional activities and its increased expression is associated with silencing
of different genes, including for example p53 [55]. Increased expression of this enzyme has been
associated to worse clinical features and AR resistance. Furthermore, the concurrent high expression
of EZH2 and TOP2A can identify a subgroup of aggressive PCa more likely to progress to metastatic
disease [56,57]. Wang et al. [58] recently correlated the histone lysine demethylase/dioxygenase
KDM8/JMJD5 expression to development of castration resistant status. This appears mainly mediated
by an interaction carried out by EZH2, which is directly targeted by KDM8. Thus, by inhibiting EZH2,
it was possible restore sensitivity to hormone therapy [58]. Furthermore, there is an increasing amount
of evidence that ADT can lead to promotion of neuroendocrine differentiation by activation of cAMP
response element-binding protein (CREB), though this mechanism is still largely unknown. CREB lead
to a state of castration resistance because its binding protein, a histone acetyltransferase, act as an
AR coactivator in transcriptional activation of AR target genes. It has been shown that ADT can
activate CREB, which enhances EZH2 activity that consequently upregulates neuroendocrine markers
and downregulates trombospondin-1, an anti-angiogenetic factor, thus promoting angiogenesis,
a characteristic of neuroendocrine tumors that appears to be highly vascularized [59,60].
Acknowledging the epigenetic mechanisms involved in PCa is important for their potential use
as targets for novel therapeutic approaches.
5. How to Overcome Resistance to AR Inhibition
As already mentioned, one of the most important hormone-inhibition-escape-strategy adopted by
prostate cancer cells is the alternative splicing of the AR which results in the expression of different
alternative AR-Vs. In brief, there are two approaches which could be adopted to overcome this
alternative splicing: one consists on the adoption of agents able to modulate AR-Vs transcription,
while the other is the development of drugs able to target these specific alternative variants (Figure 2).
Cells 2019, 8, 43 6 of 15Cells 2019, 8, 43 6 of 15 
 
 
 Figure 2. Cont.
Cells 2019, 8, 43 7 of 15
Cells 2019, 8, 43 7 of 15 
 
 
Figure 2. Androgenesis inhibition. (A) Adrenal androgen steroidogenesis. CYP17A1: cytochrome 
P450 family 17 subfamily A polypeptide 1 with two activities: 17α-hydroxylation (green) and 17, 
20-lyase (orange); both activities are inhibited by abiraterone. CYP11A1: cytochrome P450 family 11 
subfamily A polypeptide 1. 3β-HSD: 3β-hydroxysteroid dehydrogenase. 17β-HSD: 
17β-hydroxysteroid dehydrogenase. SULT2A1: bile salt sulfotransferase. STS: steryl-sulfatase. 
DHEA: Dehydroepiandrosterone. DHEA-S: Dehydroepiandrosterone sulfate. A: abiraterone; (B) 
mechanism of action of Enzalutamide. Enzalutamide inhibits AR in several ways: competing with 
DHT for binding, inhibiting nuclear translocation, blocking DNA, and co-factor binding. E: 
enzalutamide. AR: androgen receptor. DHT: dihydrotestosterone. SRD5A: steroid 5α-reductase; 
(C,D) proposed mechanisms related to hormone inhibition resistance and experimental inhibitors 
under evaluation in clinical trials. Akt: protein kinase B; AR: Androgen Receptor; Src: 
proto-oncogene tyrosine-protein kinase Src; Ras: Ras GTPase family proteins; MEK: 
Mitogen-activated protein kinase; ERK1-2: Extracellular signal-regulated kinases; PI3K: 
Phosphoinositide 3-kinase; PTEN: Phosphatase and tensin homolog; mTOR: mammalian target of 
rapamycin; GCR: glucocorticoid receptor; GC: Glucocorticoid; T: testosterone; DHT: 
Dihydrotestosterone; KDM8: Lysine demethylase 8; JMJD5: JmjC domain containing protein 5; 
EZH2: enhancer of zeste homolog 2; BRD4: bromodomain containing protein 4; BET: Bromodomain 
and extra terminal family proteins; RB: retinoblastoma protein; E2F: transcription factors E2. 
Regarding the first approach, several strategies targeting different pathways are currently 
under investigation. 
5.1. BET Pathway 
The bromodomain and extra-terminal (BET) family proteins and the bromodomain-containing 
proteins (BRD) are able to recognize and bind acetylated lysine residues in histones and other 
proteins through their bromodomains (BDs), modulating recruitment of other proteins and 
regulating DNA transcription (Figure 2D). Different BRD are able to interact with AR in nucleus, 
the more common association being the BRD4-AR interaction. As further evidences seem to show a 
key role of this protein as mediator of AR and AR-Vs transcription, the inhibition of BET pathways 
is an attractive option to overcome resistance to androgen inhibition [61,62]. To date, a phase I/II 
clinical trial is currently evaluating safety and clinical activity of the combination between 
Enzalutamide and the BET inhibitor ZEN003694 (NCT02711956, Figure 2D) in patients with 
mCRPC while two phase I studies are testing safety profile of ABBV-774 alone (NCT03360006) or in 
Figure 2. Androgenesis inhibition. (A) Adrenal androgen steroidogenesis. CYP17A1: cytochrome
P450 family 17 subfamily A polypeptide 1 with two activities: 17α-hydroxylation (green) and
17, 20-lyase (orang ); both activities are inhibited by abiraterone. CYP11A1: cytochr me P450
family 11 subfamily A polypeptide 1. 3β-HSD: 3β-hydroxysteroid dehydr genas . 17β-HSD:
17β-hydroxysteroid dehydrogenase. SULT2A1: bile salt sulfotransferase. STS: steryl-sulfatase.
DHEA: Dehydroepiandrosterone. DHEA-S: Dehydroepiandrosterone sulfate. A: abiraterone;
(B) mechanism of action of Enzalutamide. Enzalutamide inhibits AR in several ways: competing
with DHT for binding, inhibiting nuclear translocation, blocking DNA, and co-factor binding.
E: enzalutamide. AR: androgen receptor. DHT: dihydrotestosterone. SRD5A: steroid 5α-reductase;
(C,D) proposed mechanisms related to hormone inhibition resistance and experimental inhibitors
under evaluation in clinical trials. Akt: protein kinase B; AR: Androgen Receptor; Src: proto-oncogene
tyrosine-protein kinase Src; Ras: Ras GTPase family proteins; MEK: Mitogen-activated protein kinase;
ERK1-2: Extracellular signal-regulated kinases; PI3K: Phosphoinositide 3-kinase; PTEN: Phosphatase
and tensin homolog; mTOR: mammalian target of rapamycin; GCR: glucocorticoid receptor;
GC: Glucocorticoid; T: testosterone; DHT: Dihydrotestosterone; KDM8: Lysine demethylase 8; JMJD5:
JmjC domain containing protein 5; EZH2: enhancer of zeste homolog 2; BRD4: bromodomain containing
protein 4; BET: Bromodomain and extra terminal family proteins; RB: retinoblastoma protein; E2F:
transcription factors E2.
Regarding the first approach, several strategies targeting different pathways are currently
under investigation.
5.1. BET Pathway
The bromodomain and extra-terminal (BET) family proteins and the bromodomain-containing
proteins (BRD) are able to recognize and bind acetylated lysine residues in histones and other proteins
through their bromodomains (BDs), modulating recruitment of other proteins and regulating DNA
transcription (Figure 2D). Different BRD are able to interact with AR in nucleus, the more common
association being the BRD4-AR interaction. As further evidences seem to show a key role of this
protein as mediator of AR and AR-Vs transcription, the inhibition of BET pathways is an attractive
option to overcome resistance to androgen inhibition [61,62]. To date, a phase I/II clinical trial is
currently evaluating safety and clinical activity of the combination between Enzalutamide and the BET
inhibitor ZEN003694 (NCT02711956, Figure 2D) in patients with mCRPC while two phase I studies
are testing safety profile of ABBV-774 alone (NCT03360006) or in combination with the Bcl-2 inhibitor
Venetoclax (NCT02391480, Figure 2D) in solid and hematological tumors.
Cells 2019, 8, 43 8 of 15
5.2. Cyclins
Increasing interest in the development of cyclin inhibitors is mainly due to the important results
obtained in metastatic breast cancer. Cyclins are a heterogeneous group of proteins which acts in
different point of cell cycle. Thus, we recognized four types of cyclin according to the different phase of
cell division: G1/S cyclins, S cyclins, M cyclins and G1 cyclins. In prostate cancer, there are evidences
that seem to correlate cyclins expression to AR expression, radio-resistance and hormone inhibition
resistance [63–65]. Of interest, Pal et al. performed an evaluation on circulating tumor cells (CTCs)
of patients with prostate cancer who received abiraterone or enzalutamide [65]. They evaluated
different genetic expression of CTCs in patients with sensitivity or acquired resistance to treatment.
Of the several potential genes correlated to acquired resistance, an up-regulation of cyclin D1 in drug
resistant CTCs was observed. Furthermore, when they induced cyclin hyper-expression in tumor cell
tumor culture they observed that cells were refractory to enzalutamide production. This resistance
was partially avoided through the adoption of cyclin-dependent kinase inhibitors. Not surprisingly,
the adoption of cyclin-dependent kinase inhibitors is a promising strategy under investigation alone
(palbociclib, NCT02905318, Figure 2D) or in combination with enzalutamide (ribociclib, NCT02555189,
Figure 2D) or docetaxel (ribociclib, NCT02494921).
5.3. Histone Deacetylase Inhibitors
The non-selective histone deacetylase inhibitor panobinostat (Figure 2D) and the suberolylanilide
hydroxaminic acid vorinostat (Figure 2D) have been evaluated in association with docetaxel in
patients with advanced solid malignancies (vorinostat) and metastatic CRPC (panobinostat) [66–69].
Unfortunately, the combination of vorinostat and docetaxel resulted in excessive dose-limiting
toxicity [66] while a better safety profile has been observed with the combination of panobinostat and
docetaxel [67]. More recently, a phase II study evaluating intravenous panobinostat failed to show
significant clinical activity of this drug [68]. Despite these results, a study carried out by Ferrari et al.
on xenograft and isogenic cell line demonstrated that the addiction of panobinostat to bicalutamide
prolonged tumor sensitivity to bicalutamide, suggesting an adoption of this drug in combination with
androgen deprivation therapy [69]. Of note, the combination between an acetylase inhibitor (CCS1477)
and abiraterone is under evaluation in a phase I/II trial (NCT03568656).
5.4. EZH2
As already discussed, inhibition of the histone methyltransferase EZH2 could restore sensitivity
to hormone therapy. Currently, there are two ongoing phase I/II studies evaluating the EZH2 inhibitor
CPI-1205 (Figure 2D) in association with Abiraterone and enzalutamide (NCT03480646) as well as the
combination between the androgen receptor antagonist SHR3680 (Figure 2C) and the EZH2 inhibitor
SHR2554 (NCT03741712, Figure 2D).
Other approaches have been considered to overcome acquired resistance to hormonal inhibition.
As already described, specific agents able to target altered splicing ARVs are under evaluation as
well as drugs with higher antagonistic power against AR. However, several other altered pathways
seem to be implicated in the development of AR inhibition resistance; thus, the adoption of combined
treatment between these pathways and AR could be a winning strategy.
5.5. PI3K-AKT-mTOR
Through the regulation of an extraordinary number of effectors able to modulate
phosphorylation, transcription or translation of several target points the phosphoinositide-3-kinase
(PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway modulate cellular process able to
promote protein synthesis, proliferation, survival, differentiation, and metabolism. Not surprising,
due to the large number of functions regulated by this pathway alteration in PI3K-AKT-mTOR are quite
frequent in several tumor types [70]. About prostate cancer, deregulation of PI3K-AKT-mTOR signaling
Cells 2019, 8, 43 9 of 15
could be observed in 42 up to 100% of cases in localized and advanced disease, respectively [71].
Regarding the interaction between AR and PI3K-AKT-mTOR signaling, some in vivo studies have
demonstrated that AR inhibition in mouse with PTEN loss could enhance PI3K-AKT-mTOR signaling
mainly through the down-regulation of PHLPP, which is a negative regulator. PTEN is a tumor
suppressor gene downregulated in approximately 50% of CRPC and its loss, leading to activation of
PI3K-AKT-mTOR pathway, is associated with the development of castration resistance and poor
outcomes [56,72]. AKT enhanced activity reduces AR dependence of prostate cancer cell; thus,
it contributes to the development of castration resistant status [73–75]. Of interest, inhibition of
PI3K-AKT-mTOR pathways leads to more aggressive tumors with acquired neuroendocrine features
through the degradation of RE-1 silencing transcription factor (REST) protein [76]. Furthermore,
the concomitant inhibition of AKT pathway and AR signaling seems to be correlated to an
enhanced REST depletion and consequent promotion of differentiation toward a neuroendocrine
subtype [76]. Currently, there are some AKT inhibitors under evaluation as mono-treatment (AZD5363,
NCT02121639, Figure 2C) or in association with abiraterone (Ipasertib, NCT03072238, Figure 2C),
which should be carefully considered taking into account the data suggesting the interaction between
these two pathways in enhancing neuroendocrine differentiation.
5.6. SRC
The SRC gene encodes the proto-oncogene tyrosine protein kinase Src which plays an important
role during embryogenic development and cell-growth. Evidences about its correlation with Androgen
Receptor pathways and development of castration resistant status are further increasing. Szafran et al.
performed an AR high content analysis to characterize the effects of specific compounds including Akt,
Abl, and Src inhibitor on AR-V7 expression demonstrating that all these drugs were able to reduce
the expression of this splice variant [77]. Moreover, Src seems to be able to promote translation to
CRPC through sensitization of AR to intracrine androgen levels by the development of canonical and
non-canonical Androgen receptor binding site associated genes [78]. This has led to the development of
a combined strategy between the Src inhibitor dasatinib (Figure 2C), enzalutamide, and MEK inhibitor
(NCT01990196) currently under investigation.
5.7. Other Strategies to Overcome Hormone Inhibition Resistance
Several compounds able to directly inhibit the AR are under investigation. Of these,
TAS3681 (Figure 2C,D) is an oral AR antagonist able also to down-regulate AR. Additionally, this drug
is able to inhibit the AR-V7 splice variants and so it seems to be active also in patients refractory to new
anti-androgen inhibition [79]. Thus, a phase I study is evaluating its safety in patients with metastatic
advanced prostate cancer (NCT02566772).
Other AR inhibitor and antagonist with higher AR affinity are also under investigation in different
setting of the disease, alone or in association with other compounds (NCT02711956, NCT02972060,
NCT02691975, NCT02826772, NCT02987829, NCT02933801, NCT03314324). ODM-208 (Figure 2A) is a
small molecule able to target the CYP11A1 which is a key enzyme able to catalyze conversion from
cholesterol to pregnenolone. Compared to Abiraterone which is a CYP17 inhibitor, it acts in an earlier
step of androgen and steroid hormones development, preventing the synthesis of androstenedione,
testosterone and also, deoxycorticosterone, and aldosterone. A phase I/II study is currently testing
this drug and evaluating its safety (NCT03436485).
Another approach is represented by the administration of drugs able to antagonise
the glucocorticoid receptor and so acting as antiglucocorticoid. Relacorilant (Figure 2C),
an antiglucocorticoid conceived for patients with Cushing syndrome or alcoholism, is currently
under evaluation in a phase I trial in combination with enzalutamide (NCT03674814), while the
association between enzalutamide and the glucocorticoid receptor antagonist CORT12529 (Figure 2C)
is under evaluation in a phase I/II trial (NCT03437941).
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6. Conclusions
Management of patients progressed to standard androgen deprivation therapy have included
agents able to improve hormone inhibition and are also active in castration-resistant prostate cancer.
It is probable that combination strategies and development of new drugs will extend the benefit of
these drugs and improve survival and clinical benefit of our patients. This goal is possible thanks to
the increasing knowledge about genetic mechanisms related to acquisition of castration resistant status
and this highlights the need of genomic assessment of tumor cells in different times of the disease.
In this line of thought, a parallel evolution that should be considered is the adoption of techniques
able to assess circulating tumor cells and DNA more and more effectively.
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